Leflunomide Washout for Pregnancy
Women planning pregnancy must discontinue leflunomide and undergo cholestyramine washout (8 grams three times daily for 11 days) to achieve undetectable serum metabolite levels (<0.02 mg/L), verified by two separate tests at least 14 days apart. 1
Washout Protocol
The FDA-mandated drug elimination procedure is straightforward:
- Administer cholestyramine 8 grams three times daily for 11 days (days do not need to be consecutive unless rapid elimination is required)
- Verify plasma M1 metabolite levels <0.02 mg/L by two separate tests at least 14 days apart
- If levels remain >0.02 mg/L, repeat cholestyramine treatment 1
Critical Timing Considerations
Without cholestyramine washout, it may take up to 2 years to reach safe plasma levels due to individual variation in drug clearance 1. This prolonged elimination occurs because leflunomide's active metabolite (A77126/M1) undergoes extensive enterohepatic recirculation with a half-life of approximately 2 weeks.
The 2020 ACR guidelines strongly recommend cholestyramine washout if detectable serum levels exist prior to or as soon as pregnancy is confirmed, noting that once metabolite is undetectable, risks of pregnancy loss and birth defects are not elevated 2.
If Pregnancy Occurs on Leflunomide
Immediately initiate cholestyramine washout and refer to maternal-fetal medicine specialist 2. The ACR strongly recommends immediate referral to maternal-fetal medicine, pregnancy medication specialist, or genetics counselor as standard practice for inadvertent exposure 2.
Evidence suggests that rapidly lowering metabolite levels through cholestyramine at the first delay of menses may decrease fetal risk 1. Research data from 64 pregnant women exposed to leflunomide (95.3% received cholestyramine) showed no significant increase in major structural defects (5.4%) compared to unexposed RA patients (4.2%) or healthy controls (4.2%), similar to the 3-4% baseline population risk 3.
Pre-Conception Planning
The 2025 EULAR guidelines note that leflunomide should be avoided in breastfeeding women due to insufficient safety data 4. However, leflunomide can be continued in male patients attempting to conceive, as current evidence shows no negative impact on birth outcomes 4.
Common Pitfalls
- Do not assume adequate washout without laboratory verification - individual clearance varies dramatically
- Do not delay cholestyramine if pregnancy is suspected - early intervention may reduce fetal risk
- Do not rely on time alone - without cholestyramine, elimination takes up to 2 years 1
- The 11-day cholestyramine course is the minimum; additional treatment may be needed if levels remain elevated 1